Kadcyla (trastuzumab emtansine) is Roche's 'next generation' version of its hugely successful breast cancer drug Herceptin for people with HER2 positive breast cancer.

NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

The cost of Kadcyla can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Kadcyla. As with all ...